文献速递肝病

NASH药物治疗的候选人群选择

Treatment Candidacy for Pharmacologic Therapies for NASH.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-03-10

本文综述非酒精性脂肪性肝病的自然史、NASH在研治疗药物及各类评估方法。基于现有知识,讨论了NASH的目标治疗人群,以及无创检测是否已可用于指导患者选择和治疗反应评估。

要点

  • NASH已成为肝硬化和肝细胞癌的重要原因,超过50种治疗药物处于不同临床开发阶段。
  • 奥贝胆酸在3期REGENERATE研究中达到纤维化改善且NASH不恶化的中期组织学终点。
  • 多种药物处于3期试验,目标是通过FDA subpart H途径获得条件性注册。

核心结论

  • 基于当前知识,需要明确NASH的目标治疗人群,并评估无创检测是否已可用于指导治疗选择和疗效评估。

研究设计与样本

  • 综述类文章,回顾非酒精性脂肪性肝病的自然史、NASH在研治疗药物及各类评估方法。

主要发现

  • NASH已成为肝硬化和肝细胞癌的重要原因之一,超过50种治疗药物处于不同临床开发阶段。
  • 奥贝胆酸在3期REGENERATE研究中达到纤维化改善且NASH不恶化的中期组织学终点,患者正在随访长期临床结局。
  • 多种药物处于3期试验,目标是通过FDA subpart H途径获得条件性注册。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nonalcoholic steatohepatitis (NASH) has emerged as one of the important causes of cirrhosis and hepatocellular carcinoma, and over 50 therapeutic agents are in various phases of clinical development. Recently, obeticholic acid has achieved the interim histological endpoint of fibrosis improvement with no worsening of NASH in the phase 3 REGENERATE study, and now patients are being followed for long-term clinical outcomes. Several drugs are in Phase 3 trials with a goal to achieve conditional registration under the subpart H pathway by the United States Food and Drug Administration (FDA). It is thus timely to consider the current situation and the way ahead in the management of NASH. In this article, we review the natural history of nonalcoholic fatty liver disease, upcoming treatments for NASH and various assessments. Based on the current knowledge, we discuss what should be the target treatment population and whether noninvasive tests are ready to guide NASH treatments both for patient selection and evaluation of treatment response.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rowe IA, Wong VW, Loomba R, et al. Treatment Candidacy for Pharmacologic Therapies for NASH. Clin Gastroenterol Hepatol. 2021. PMID: 33711479. doi:10.1016/j.cgh.2021.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。